← Back to Home

A Clearer View of the Neuronal Ion Transport Protein NBCn2 Opens an Early Path for Epilepsy Drug Discovery

Cryo-electron microscopy has revealed the three-dimensional structure of NBCn2 and guided the research team to the first inhibitory molecules; they can already alter neural signaling ex vivo, but a long process of validation remains before they can become epilepsy drug candidates.

By SURL BioNews

Epilepsy drug discovery often begins with ion channels and neurotransmitters, but how neurons regulate acid-base and ion balance may likewise influence firing states. A team at the Icahn School of Medicine at Mount Sinai in the United States has now determined the high-resolution structure of the neuronal transport protein NBCn2 for the first time, making this protein—which previously lacked specific tools—a target that can begin to be studied using molecular design methods.

Published in *Nature Communications*, the study combined cryo-electron microscopy, computational modeling, and AI structure prediction to map the molecular architecture of NBCn2 and how sodium ions and bicarbonate-related substrates may enter and bind to the protein. The researchers found that its ion-binding configuration differs from those of several closely related transport proteins. If this difference can be further confirmed, it may help in designing compounds with greater selectivity that are less likely to interfere with other members of the same family.

The structure was used not only as a static image but also to narrow the compound search space. Through virtual screening, the team examined millions of molecules and identified a series of compounds capable of inhibiting NBCn2-mediated transport, then used cryo-electron microscopy to study how they bind and inhibit the protein. This process illustrates AI’s specific role in the research: helping to fill gaps in structural hypotheses and support screening, while the actual inhibitory effects still had to be validated in cell and tissue experiments.

The candidate molecules were subsequently tested in cells, primary neuronal cultures, and mouse brain slices. One investigational lead compound reduced electrical signal transmission between neurons, indicating that inhibiting NBCn2 may indeed alter neural network activity. However, these findings come from early experimental systems and have not yet shown that the compounds can reduce seizures in animal models of epilepsy, and there are no human efficacy or safety data.

The study’s practical value therefore lies first in providing “probes,” rather than delivering a drug ready to enter clinical trials. Subsequent work must improve potency, selectivity, and drug properties; clarify the potential adverse effects of long-term intervention in the brain’s acid-base and ion balance; and test in animal and human-derived disease models which types of epilepsy, if any, NBCn2 may be applicable to. The paper also discloses that several authors are inventors on a Mount Sinai provisional patent covering NBCn2 inhibitory probes, a relationship that should also be considered when interpreting their translational potential.

Background

AI structure prediction is moving drug discovery beyond the folding of individual proteins toward modeling interactions among proteins, ions, and small molecules; the NBCn2 study is a concrete example of this approach. But a more detailed molecular map can only improve the efficiency of generating and screening hypotheses; it cannot replace disease models, toxicology, pharmacokinetics, or clinical trials. For epilepsy research, the genuinely new development at present is that a difficult-to-study brain protein finally has a testable structure and tool molecules—not that a new therapy has arrived.

References

  1. Icahn School of Medicine at Mount Sinai
  2. Nature Communications
  3. Medical Xpress